Immunotech Biopharm Ltd. announced that 6B11-OCIK Injection, one of the Group's pipeline products, has completed the first patient enrollment for its Phase I clinical trial in the PRC on 29 January 2022, which marked the milestone of the Group's development in its product pipeline. Based on the progress of clinical trial for 6B11-OCIK Injection and barring unforeseen circumstances, it is expected that the targeted patient enrollment will complete in as early as the third quarter of 2022 and the preliminary analysis and results will be published in 2022. 6B11-OCIK Injection is the monoclonal anti-idiotypic antibody prepared by Beijing Weixiao Biotechnology Development Limited, a subsidiary of the Company, with COC166-9 immunised mice with monoclonal antibody to mimic ovarian cancer-related antigen OC166-9. The use of 6B11 can induce specific anti-ovarian cancer humoral and cellular immune antibodies in vitro, which can be cultured and proliferated in vitro (6B11-OCIK Injection) and infused back to the subject to achieve the purpose of specifically killing tumour cells.